{
  "docId": "019de070-182a-72ba-952e-2b048c610e12",
  "docSlug": "cea7bfa85dc209a87c7b2adf6cd4697f",
  "documentTitle": "Aeglea BioTherapeutics | Investor Presentation Deck | 22 slides",
  "authorId": "aeglea-biotherapeutics",
  "authorName": "Aeglea BioTherapeutics",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2020-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 21,
  "pageCount": 22,
  "prevPage": 20,
  "nextPage": 22,
  "slideType": "solution",
  "function": "present_solution",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": null,
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-182a-72ba-952e-2b048c610e12/21",
  "deckHref": "/decks/019de070-182a-72ba-952e-2b048c610e12",
  "deckJsonHref": "/decks/019de070-182a-72ba-952e-2b048c610e12.json",
  "deckAnchorHref": "/decks/019de070-182a-72ba-952e-2b048c610e12#slide-21",
  "components": [
    {
      "bbox": {
        "h": 0.5,
        "w": 0.45,
        "x": 0.06,
        "y": 0.235
      },
      "kind": "list",
      "text": "Lead assets in three areas of high unmet medical need; Looking beyond the conventional, redefining the potential of human enzymes to deliver disruptive solutions; Driven by the urgent needs of the communities we serve; Pursuing our vision to become the premier human enzyme company; Changing the lives of patients and their families now and for the future",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6242f565-c584-4a5c-86a9-2e3e7e824dd0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.7,
        "w": 0.4,
        "x": 0.56,
        "y": 0.2
      },
      "kind": "table",
      "text": "Pegzilarginase (Pivotal Phase 3, Arginase 1 Deficiency, Metabolism); ACN00177 (Homocystinuria); AEB5100 (Cystinuria, Nephrology)",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "05c565eb-e203-418a-8470-177b94b0be1d",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.92,
        "x": 0.04,
        "y": 0.06
      },
      "kind": "title",
      "text": "A Disruptive Platform Producing A New Generation of Human Enzyme Solutions",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e9215855-a5b2-4f5b-a25d-5b26ebf1acc9",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 22,
      "from": 21,
      "beatId": "c18dcf56-32be-4983-8a02-496b701759d9",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Action",
      "beatSlug": "monroes-sequence-action",
      "evidence": "A Disruptive Platform Producing A New Generation of Human Enzyme Solutions",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Resolution",
      "parentBeatSlug": "resolution"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}